Reaffirming revenue guidance, especially in the multi-billion dollar range, is a positive signal to investors about the company's stability and growth prospects. This announcement is likely to instill confidence among investors, potentially leading to a positive short-term impact on Jazz Pharmaceuticals' stock price. The specificity of the guidance range further enhances the credibility of the company's financial forecasting and operational stability.